Suramin for Recluse Spider Bites

苏拉明治疗隐士蜘蛛咬伤

• 批准号: 10258847
• 负责人: JONATHAN A GREEN
• 金额: $ 18.89万
• 依托单位: STOECKER & ASSOCIATES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10258847
• 关键词: African Trypanosomiasis; Analysis of Variance; Animal Model; Animals; Area; Back; Binding; Biopsy Specimen; Biotechnology; Bite; Businesses; Cattle; Cavia; Child; Collaborations; Dermatologist; Diagnosis; Diagnostic tests; Dose; Effectiveness; Elderly; Emergency department visit; Enzyme-Linked Immunosorbent Assay; Film; Formulation; Goals; Habitats; Health; Hemolysis; Home; Hospitalization; Hour; Human; Incidence; Injections; Interdisciplinary Study; Intervention; Lesion; Liposomes; Measures; Midwestern United States; Missouri; Modality; Modeling; Morbidity - disease rate; Necrosis; New Zealand; Oryctolagus cuniculus; Pain; Patients; Peroxidases; Persons; Phase; Phospholipase; Phospholipase D; Physicians; Polymers; Population; Positioning Attribute; Pregnancy Tests; Principal Investigator; Reaction; Research; Route; Rural; Scientist; Severities; Spider Bites; Spider Venoms; Spiders; Suramin; System; Techniques; Testing; Therapeutic; Time; Topical application; United States; Universities; Venoms; Visit; Work; accurate diagnosis; base; effective therapy; experience; in vivo; in vivo Model; innovation; multidisciplinary; necrotic tissue; new technology; novel; therapy design; treatment optimization; wound; wound healing

Suramin for Recluse Spider Bites: SpiderTek, a biotechnology company that developed the first spider bite diagnostic test, proposes therapy for bites due to Loxoscelesthre erecclulseusspiade,r, using suramin, a century-old treatment for African sleeping sickness. A population of 80 million in the South-Central US shares homes with the recluse spider. Each year, an estimated 30,000 persons suffer recluse spider bites that can result in painful, slowly healing wounds. Hundreds of patients annually develop hemolysis, which can be severe, especially in children and older persons. Therapy in the United States is limited to supportive measures. With accurate diagnosis now available, the next step is to develop an effective treatment. We propose a therapeutic solution based on the discovery that the suramin molecule binds to phospholipase D, the active component in the recluse spider venom. The overall objective of the proposed research is to develop an optimized therapy for these spider bites. Phase I will determine the therapeutic constraints of suramin therapy in loxoscelism. First, we will determine the range of the effective in-vivo dose as we vary suramin dose. Next, we will determine the time window for effective treatment—how soon after the bite does treatment have to occur to be effective? Finally, we will compare suramin injection with a novel topical administration technique, which will enable patients to avoid emergency room visits. The proposed research will provide basic proof-of-concept for our proposed suramin therapy for loxoscelism and enable us to develop a human trial in planned Phase II research. Finally, our interdisciplinary research team involves collaboration between privately held SpiderTek and the University of Missouri. Both entities are located in rural Missouri, where the incidence of loxoscelism is high. The team features multidisciplinary expertise, including an animal scientist, developer of the first ELISA-based pregnancy test for cattle as well as our spider bite diagnostic test, a dermatologist with extensive experience in recluse spider bites, and a widely recognized developer of topical formulations. With previous successful experience in bringing the first spider bite test to market and with strong existing collaborations between the principal investigator and his colleagues, the team is uniquely positioned to perform the proposed research.

Suramin for Repluse Spider叮咬：Spidertek，一家生物技术公司，开发了第一个蜘蛛咬 诊断测试，提案治疗loxsoscelesthre ereccluluseusspiade，r，使用苏拉蛋白，a 非洲睡病的百年治疗。美国中南部的8000万人口 带有隐居蜘蛛的房屋。每年，估计有30,000人遭受隐居蜘蛛碎片 导致痛苦，缓慢地康复的奖金。每年数百名患者发生溶血，可以是 严重，尤其是在儿童和老年人中。在美国的治疗仅限于支持 措施。有了准确的诊断，下一步是开发有效的治疗方法。我们 提案基于发现的治疗溶液，即苏拉米蛋白分子与磷脂酶D的结合， 隐居蜘蛛毒液中的活性成分。 拟议的研究的总体目的是为这些蜘蛛碎片开发优化的疗法。阶段 我将确定苏拉明疗法在洛克斯科主义中的治疗约束。首先，我们将确定范围 随着我们改变苏拉蛋白剂量的有效体内剂量。接下来，我们将确定有效的时间窗口 治疗 - 咬合后不久，必须进行治疗是否有效？最后，我们将比较 用新型的局部给药技术注射苏拉蛋白，这将使患者避免紧急 客房访问。拟议的研究将为我们提议的苏拉明疗法提供基本的概念证明 Loxsoscelism，使我们能够在计划的II期研究中开发人类试验。 最后，我们的跨学科研究团队涉及私人持有的Spidertek与 密苏里大学。这两个实体都位于密苏里州农村，那里的Loxsoscelism事件很高。 该团队具有多学科专业知识，包括动物科学家，第一个基于ELISA的开发人员 牛的妊娠试验以及我们的蜘蛛咬伤诊断测试，这是一名具有丰富经验的皮肤科医生 隐居蜘蛛碎片，以及局部公式的广泛认可的开发人员。与以前的成功 将首次蜘蛛咬合测试带入市场的经验以及在现有的强烈合作之间 首席研究员及其同事，该团队在执行拟议的研究方面拥有独特的位置。